Market research
1AD.AU AdAlta Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.19
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000001AD2
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.19
About
About AdAlta Limited
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1AD.AU discussion.
5 years, 5 months ago
AdAlta Limited is currently in a long term downtrend where the price is trading 0.9% below its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 44.8.
AdAlta Limited's total revenue rose by 99.5% to $806K since the same quarter in the previous year.
Its net income has increased by 24.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 74.5% to $-399K since the same quarter in the previous year.
Based on the above factors, AdAlta Limited gets an overall score of 4/5.